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What’s already known about this topic? 
 Chronic pain is the most prominent and debilitating complaint in Pachyonychia congenita (PC) 
 The origin of the pain is not established hence also an appropriate intervention 
 Histological studies found alterations in sensory innervation  
 
What does this study add? 
 Systemic sensory testing revealed hypoesthesia along with mechanical hyperalgesia and 
allodynia (pain due to a non-painful stimulus) in the painful body regions  
 Causative mutation and gene harboring did not affect any of these features 
 The clinical and physiological characteristics of the pain suggest a possible neuropathic origin 
 Neuropathic pain medications may be beneficial for PC patients 
  
 
Abstract 
Background: Pachyonychia congenita (PC) is a rare autosomal dominant skin disease with 
chronic pain being the most prominent complaint. Histological studies showing alterations in sensory 
innervation along with few reports on alterations in mechanical sensitivity suggest that PC may be a 
form of neuropathy.  
Objective: To systematically evaluate sensory function of PC patients vs. controls, here for the 
first time, in order to investigate PC pathophysiology.  
Methods: Patients (n=62) and controls (n=45) completed the McGill and Douleur 
Neuropathique-4 (DN4) questionnaires. Sensory testing included: detection and pain thresholds, 
pathological sensations, conditioned pain modulation (CPM) and temporal summation of pain (TSP).  
Results: A moderate-severe chronic pain in the feet, throbbing and stabbing in quality, was 
highly prevalent among PC patients (86%) and especially debilitating during weight bearing. In 
addition, the majority of patients had DN4 score >4 (62%), static allodynia (55%) and tingling (53%) 
in the feet. Compared to controls, PC patients exhibited thermal and mechanical hypoesthesia and 
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mechanical hyperalgesia in the feet. CPM was reduced among the patients, and associated with 
more enhanced feet mechanical hyperalgesia. The specific gene and nature of the causative 
mutation did not affect any of these features. 
Conclusion: Although thermal and mechanical hypoesthesia may result from thicker skin, its 
presentation in painful regions along with mechanical hyperalgesia and allodynia point towards the 
possibility of neuropathic changes in PC. The clinical features and DN4 scores support this possibility 
and therefore neuropathic pain medications may be beneficial for PC patients.  
Keywords: Pachyonychia congenita, chronic pain, diagnosis, neuropathic pain 
Introduction 
Pachyonychia congenita (PC) is an autosomal dominant skin disease caused by a mutation in 
one of 5 genes encoding different keratins: KRT6A (K6a), KRT6B (K6b), KRT6C (K6c), KRT16 (K16) or 
KRT17 (K17). These keratins are expressed in keratinocytes of the nail, palmoplantar skin, mucosa, 
and hair, leading to clinical manifestations at these sites.1-3 PC affects males and females equally 
with an estimated prevalence of 0.9 cases per million.4 
Clinically, PC features a triad of nail dystrophy, plantar keratoderma and plantar pain presenting 
at birth or in early childhood. The pain is severe and debilitating, especially on weight-bearing areas 
and a significant limiting factor with regard to activity of daily living. Plantar pain specifically has the 
most profound impact on quality of life. Other common clinical manifestations include: cysts, 
follicular hyperkeratosis, oral leucokeratosis, hyperhidrosis and palmar keratoderma.5,6 The pain 
reported by PC patients has not been formally characterized and therefore its pathophysiology 
remains elusive. As no specific treatment or cure is known for PC, therapy is generally directed 
towards symptomatic improvement.6,7 A systematic evaluation of the chronic pain and sensory 
profile of patients with PC is necessary to delineate the pathophysiology of the pain and design 
efficient pain management. 
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To the best of our knowledge only two studies conducted sensory testing among patients with 
PC. Wallis et al.8 reported alterations in mechanical detection and pain thresholds in the feet of PC 
patients yet the nature of the alteration was not reported probably due to lack of a control group. 
Pan et al.9 reported a lower pressure-pain thresholds in PC-affected plantar skin of 10 patients 
compared to intact skin along with less sweat gland innervation and Meissner corpuscles, and more 
Merkel cells and blood vessels in PC-affected skin as reveled by skin biopsies. Consequently, the 
function of non-nociceptive nerve fibers has not been evaluated in PC and the function of 
nociceptive fibers was evaluated on a small sample size and requires additional testing. 
Furthermore, pain modulation capacity of patients with PC, has never been evaluated previously and 
is essential for the understanding of chronic pain pathology.  
Due to the dearth of information regarding the sensory profile of PC patients and the possibility 
that such information can shed light on the pathophysiology PC and lead to better pain 
management, the aims were to evaluate, among PC patients vs. controls: 1) the somatosensory 
function and pain modulation capacity, and 2) the association between these factors and the chronic 
pain characteristics. 
Material and Methods  
Subjects 
107 individuals participated, comprising two groups: (1) 62Pindividuals diagnosed as having 
genetically confirmed Pachyonychia Congenita (PC group; 29 males and 33 females, average age 
44.8±16.4 years) and (2) 45 sex- and age-matched healthy controls (HC group; 18 males and 27 
females, average age 39.2±15.5 years). PC patients with mutations in KRT6A or KRT16 were recruited 
through the International Pachyonychia Congenita Research Registry (IPCRR). Healthy subjects were 
recruited among employees of the Tel-Aviv Medical Center as well as among members of the PC 
Project personnel.  
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The study was approved by the Western Institutional Review Board (WIRB 20111060). A written 
informed consent was obtained from all subjects, according to the Declaration of Helsinki guidelines 
after they received a full explanation of the study protocol and goals. 
Equipment 
1. Thermal Stimulator 
Heat stimuli were delivered using a Peltier-based computerized thermal stimulator (TSA II, 
Medoc Ltd., Ramat-Ishay, Israel), with a 3 x 3 cm contact probe. The probe was attached to the 
testing site by means of a Velcro band. In case the testing site was too large, the examiner held the 
probe. 
2. Water bath 
Cold stimuli were delivered using a 4 liter, cylindrical water bath filled with ice water and 
maintained at a temperature of 10°C. 
3. Pressure algometer 
Pressure stimuli were delivered, using a hand-held pressure algometer (Somedic Sales AB, 
Algometer type II, Sweden) with a 1cm diameter contact probe that is pressed against the skin. The 
exertion of a constantly increasing rate of pressure is monitored on the display.  
4. Semmes-Weinstein monofilaments 
Mechanical stimuli were applied with Semmes-Weinstein Monofilaments (North Coast Medical 
Inc., Morgan Hill, California) comprised of 20 calibrated monofilaments, with sizes ranging between 
1.65-6.65, inducing a calibrated force ranging between 0.008-300 gm, respectively. 
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5. Visual analog scale (VAS) 
 Chronic and experimental pain intensity was measured with a VAS consisting of a horizontal 
red bar (the visual side) exposed to the subject, while the side facing the experimenter displays an 
analogue scale with values between 0="no pain sensation" and 10="the most intense pain sensation 
imaginable." Subject moved the inner slider according to their pain experience.  
Sensory testing 
1. Sensory thresholds 
Sensory detection thresholds were measured to evaluate the sensitivity of the nervous system 
to innocuous stimuli and to evaluate conduction in C fibers (warmth threshold), A-delta fibers (cold 
threshold) and A-beta fibers (touch threshold).11 Warm and cold detection thresholds were 
measured with the computerized thermal stimulator .12 Mechanical detection threshold was 
measured with the Semmes-Weinstein monofilaments.13 Pain thresholds were measured in order to 
evaluate the sensitivity of the nervous system to noxious stimuli and to evaluate conduction in 
nociceptive C fibers and A-delta fibers. Heat-pain threshold (HPT) was measured with the 
computerized thermal stimulator .12 Pressure pain threshold (PPT) was measured with the pressure 
algometer.14 All thresholds were measured in the feet (painful regions) and forearms (painfree 
regions), with the method of Limits in which a series of stimuli are presented at a gradually 
increasing magnitude and subjects are instructed to inform of the tested sensation. 
2. Conditioned pain modulation (CPM) 
CPM is an experimental paradigm representing the spinal-bulbar-spinal inhibitory circuit termed 
diffuse noxious inhibitory control (DNIC), mediated by the brain stem subnucleus reticularis 
dorsalis.15,16 DNIC refers to inhibition of pain by neurons outside the area from which the nociceptive 
input originated and it was measured as an index of pain inhibition capacity. CPM was measured by 
administering a noxious stimulus to one arm (the test stimulus [TS]) and evaluating its perceived 
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intensity alone and in the presence of another noxious stimulus applied to the contralateral hand 
(conditioning stimulus [CS]).17  
3. Temporal summation of pain (TSP) 
TSP refers to a phenomenon in which perceived pain gradually increases in response to 
repeated/constant, moderately painful stimuli of fixed intensity. TSP is centrally mediated by 
frequency-dependent increments in spinal nociceptive neurons and was measured as an index of 
nociceptive excitability.18,19 Subjects immersed their hand (up to the wrist line) in a cold water bath 
(10°C) for 30 seconds and rated their pain at immersion, after 15 seconds and at the end of hand 
immersion using the VAS. The magnitude of TSP was calculated by subtracting the last from the first 
VAS rating.17 
4. Abnormal sensations 
Allodynia is pain evoked by a normally non-noxious stimulus 20 associated with hyperexcitability 
of the nervous system and often present in neuropathic pain patients. 21,22 Static and dynamic 
allodynia were measured with monofilaments .13 Hyperpathia is the emergence of a sudden, strong 
painful sensation, which persists after stimulation is turned off,20 and is also associated with 
hypereactivity of the pain system especially in neuropathic pain.23 Hyperpathia was measured with 
the thermal stimulator .13 
Questionnaires 
1. Mc'Gill pain questionnaire 
Chronic pain was quantified with the short form of the Mc'Gill pain questionnaire (MPQ) 24 and 
with VAS.  
2. DN4   
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Chronic pain patients completed the DN4 (Douleur Neuropathique-4) questionnaire, a clinician-
administered questionnaire developed and validated for the purpose of discriminating neuropathic 
pain from non-neuropathic pain.25   
Experimental design 
Testing took place in a quiet room with ambient temperature maintained constant. Subjects 
were examined on a single testing session that was preceded by a training session. Prior to testing, 
each PC patient was interviewed regarding the location of painful and pain-free body regions and 
the chronic pain characteristics (intensity, duration, quality, ameliorating and aggravating factors, 
spontaneous or evoked abnormal sensation in painful regions, etc). Patients rated chronic pain on a 
VAS and completed the MPQ. Then sensory testing commenced and included the evaluation of 
abnormal sensations and measurement of thresholds (in the pain-free volar surface of the forearm 
and in the painful distal third of the plantar surface of the foot), CPM and TSP (both tested in the 
forearms and hands only), in random order. If blisters and/or bandages prevented from testing the 
designated foot region, testing was done on an adjacent region (the mid third of the foot in most 
occasions). PPT specifically was measured in the foot due to reports of pain during weight 
bearing/walking. Testing of controls was performed at comparable body locations. The order of the 
testing with thermal and mechanical stimuli was also randomized.  
Statistical analysis 
Data were processed with IBM SPSS statistics software (version 23). Between-group 
(patients/controls, K6a/K16) comparisons were conducted with t-tests (age, time-durations, pain 
intensity, detection/pain thresholds, CPM), Man-Whitney tests (DN4) and Chi-square tests (sex, pain 
at rest/weight bearing, abnormal sensations). Repeated-measure analysis of variance (rANOVA) was 
used to analyze the time trend and group effect on TSP. Correlations between pairs of variables 
were calculated with Pearson's or Spearman's r. Multiple testing problems were addressed by using 
the False Discovery Rate procedure26 that controls for the expected proportion of falsely rejected 
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hypotheses, which is the desirable control against errors originating from multiplicity. A 2-sided p-
value <0.05 was considered statistically significant. 
Results  
Characteristics of the study groups and of the chronic pain 
Table 1 describes the group and chronic pain characteristics. Age and sex distributions were 
similar across groups. Most of the PC patients (86%) reported suffering from chronic pain, localized 
mostly in the palmar and plantar regions. Pain intensity was moderate-severe ranging between 
2.7±2.3 at its least, to 8.7±1.3 at its worst. The two mutation PC subtypes (K6a/K16) did not differ in 
chronic pain intensity. The quality of chronic pain based on the MPQ was mostly aching (87%), 
throbbing (83%), sharp (83%), stabbing (79%) and shooting (79%). The most frequent affective pain 
descriptor was tiring. Almost all the chronic pain patients (93%) reported that the pain is felt during 
weight bearing and only the minority reported pain during rest. Out of the 53 patients with chronic 
pain, 29 (55%) reported taking analgesic medications regularly and 17 (32%) reported them to 
efficiently reduce the pain. Figure 1 presents the abnormal sensations in the painful body regions, 
with allodynia, tingling and electric shocks being the most frequent. 
Sensory testing   
1. Detection and pain thresholds 
Table 2 presents the sensory thresholds. PC patients had higher thresholds for thermal 
sensation than controls in both the upper and lower limbs and also a higher touch detection 
threshold in the lower limbs, suggesting thermal and mechanical hypoesthesia. The two groups did 
not differ in heat-pain threshold; however PC patients had lower pressure-pain threshold in the 
lower limb indicative of mechanical hyperalgesia. Importantly, there were no differences in any of 
the thresholds tested between the two PC gene subtypes (not shown). 
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2. Pain modulation 
PC patients had a significantly lower ability to inhibit pain than controls (p<0.01) (Figure 2 left 
bars). Pain ratings decreased from 4.43±3.8 to 3.8±2 among PC patients (delta of -0.75 VAS units) 
and from 4.87±1.7 to 3.1±1.5 among controls (delta of -1.65). Both groups exhibited similar TSP as 
indicated by a significant effect of time (F(2,164)=163.5, p<0.001), but lack of group effect 
(F(1,82)=3.0, p=0.087) and group by time interaction (F(2,164)=0.20, p=0.81) (Figure 2 right bars). 
Pain ratings increased from 1.94±1.8 to 4.9±3 among PC patients (delta of 3.0 VAS units) and from 
2.98±2.0 to 5.9±2.5 among controls (delta of 2.9). No differences were observed in CPM or TSP 
between the two PC gene subtypes. 
3. Correlations between variables  
Neither pain intensity nor DN4 score correlated significantly with any of the sensory testing 
(Table 3). A longer chronic pain duration was associated with less intense pain, higher thermal 
detection thresholds (i.e. more pronounced hypoesthesia) but higher pressure pain threshold (i.e. 
less pronounced hyperalgesia). Pressure pain threshold correlated negatively with CPM; patients 
with more enhanced mechanical hyperalgesia in the foot had less efficient CPM.  
4. DN4 questionnaire 
The average DN4 score was 4.0±2.6 (ranging from 0 to 10) (Table 1). The majority of PC patients 
with chronic pain (62%) had DN4 score>4 suggesting positive diagnosis for neuropathic pain. 
Although sensory testing was similar for patients with DN4 score above and below a score of 4, the 
former exhibited significantly higher rates of tingling (18/33 vs. 8/28, p<0.05) and numbness (12/33 
vs. 3/28, p<0.05) and higher chronic pain intensity (MPQ 25.1±9 vs. 17.9±9, p<0.05) than the latter. 
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Discussion  
The results show that 86% of PC patients report chronic pain that was especially prominent in 
the feet and during weight bearing. In order to ascertain the nature and origin of the pain, the 
chronic pain and sensory profile were characterized and the diagnostic DN4 questionnaire was 
completed. 
Chronic pain characteristics 
The majority of patients reported moderate-strong pain of aching quality, a feature more 
typical to pain of musculoskeletal origin.27 Yet, at the same time, similarly frequent were the 
descriptors; throbbing, sharp and shooting characteristic of neuropathic pain. 22,28,29 Almost all 
chronic pain patients reported that the pain was felt mainly during weight bearing, a complaint not 
typical to neuropathic pain in which pain is usually spontaneous but may worsen during activity.22 
Some PC patients also reported that the pain is evoked or exacerbated when the affected skin is wet, 
a complaint that seems specific to PC. 
Sensory profile 
PC patients exhibited increased thermal thresholds in both the feet and forearms than controls 
indicating reduced thermal sensitivity (hypoesthesia). The thick skin of the feet due to 
hyperkeratosis may be the reason for the feet thermal hypoesthesia requiring more stimulation 
energy in order to activate the cutaneous thermo-receptors. However, the thermal hypoesthesia in 
the intact forearm is more difficult to explain. Perhaps PC patients are generally hyposensitive to 
thermal stimuli because skin thickness is increased throughout the body. Alternatively, perhaps PC 
patients are less attentive than controls to external, innocuous stimuli because of constant 
background pain.  
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Despite higher thermal detection thresholds, heat-pain thresholds in the feet were similar for 
patients and controls. This apparent discrepancy may result from a combination of thick skin and 
sensitized thermal nociceptors (pain receptors) due to PC pathology. Namely, thicker skin may 
require higher stimulation energy to produce heat-pain among PC patients than controls however if 
the nociceptors are hypersensitive in PC they require lower stimulation energy to signal pain than 
normal. Consequently the stimulation temperatures are counterbalanced leading to an apparent 
“normal” heat-pain threshold among the patients. When using pressure instead of heat for testing 
pain threshold, a modality that is not influenced by skin thickness, decreased pain threshold 
(hyperalgesia) in the feet of PC patients is revealed. This local mechanical hyperalgesia is consistent 
with the patients’ reports of pain during weight bearing and may suggest that underneath the 
hyperkeratosis the nociceptors are indeed sensitized. Wallis et al.8 reported abnormal detection of 
touch and pressure-pain among PC patients but they did not specify whether these were increased 
or decreased, information that is essential for diagnosis. Mechanical hyperalgesia, as found herein, is 
a common sign of neuropathic pain22,29,30 and its presence in the feet of PC patients indicates 
peripheral sensitization, most probably of C and A delta fiber nociceptors.31 
The normal TSP indicates that PC patients did not present generalized hyperexcitability. Yet, the 
patients did have reduced CPM compared with controls indicative of dysfunctional pain inhibition 
capacity. Such a dysfunction is common in chronic pain patients of various etiologies,15-16 including 
neuropathic pain.12,32,33 It is not clear whether deficient CPM preceded the development of the 
chronic pain in PC (and thus contributed to its emergence) or resulted from it. Although the 
magnitude of CPM did not correlate with neither the intensity nor the duration of chronic pain it did 
correlate with the mechanical hyperalgesia in the feet; the more enhanced mechanical hyperalgesia 
the less efficient CPM. This correlation suggests that the reduced ability to inhibit pain may 
contribute to one of the major features of the chronic pain in PC which is pain during weight bearing.  
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Pathological sensations 
Along with hyperalgesia, allodynia which was highly prevalent among the PC patients also 
indicate sensitization as often observed in neuropathic pain.22,31 The presence of static allodynia in 
particular, which is mediated by unmyelinated C fibers21,34 suggest that pain in PC is associated with 
nociceptive fiber sensitization. The PC patients exhibited several additional “positive signs” 
characteristic of neuropathic pain including tingling and electric-shock like sensations.22,29 
Paradoxical sensations and hyperpathia, revealed herein during thermal testing, are also reported 
among neuropathic patients,12,23,31 although these features are less frequent than allodynia.  
The DN4 questionnaire 
A score of 4 is the cut-off value for the diagnosis of neuropathic pain using the DN4 
questionnaire25 as recently validated in e.g. diabetic polyneuropathy [35], back pain [36] and 
peripheral neuropathies.37 About 62% of PC patients received a score >4, which is in agreement with 
Wallis et al.8 who used a different diagnostic tool (painDETECT). Interestingly, sensory testing was 
similar among patients with DN4 above and below a score of 4; however the latter show somewhat 
reduced frequencies of tingling and less severe chronic pain.  
Conclusions and possible mechanisms 
Neuropathic pain develops as a result of lesions or disease affecting the peripheral or central 
somatosensory nervous system.22,38 Neuropathic pain may encompass a broad spectrum of signs and 
symptoms and combinations of gain ("positive signs") and loss ("negative signs") of sensibility are 
shared across the major neuropathic pain syndromes22,23 as also found herein. The “positive” 
neuropathic symptoms characteristic of PC patients included: spontaneous electric-shock like 
sensations and tingling, allodynia and mechanical hyperalgesia. The “negative” neuropathic signs 
and symptoms included thermal and mechanical hypoesthesia although spontaneous signs (e.g., 
numbness and weakness) were not frequent among PC patients. The aforementioned signs along 
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with the pain complaints and the DN4 scores all support the possibility that the chronic pain in PC is- 
at least partly- of neuropathic origin. This does not preclude the possibility that in some patients the 
pain is of nociceptive origin, or has started as nociceptive but with the progression of the diseases 
elements of the nervous system were affected as well.  
The mechanism of chronic pain in PC is yet unclear. Pan et al.9 have recently found that painful 
PC-affected skin demonstrated multiple alterations, including increased density of Merkel Cells and 
blood vessels and reduced numbers of Meissner corpuscles and densities of small unmyelinated 
nerve fibers compared to intact skin. These findings support the possibility that damage to 
peripheral nerve fibers may be involved in the mechanism of pain in PC. Damage to sensory nerve 
fibers can generate a chain of events leading to peripheral sensitization.29 The observed hyperalgesia 
and allodynia in the PC-affected regions herein may well be manifestations of peripheral 
sensitization. In addition, changes in the function of ion channels, specifically that of transient 
receptor potential channels,39 may possibly contribute to peripheral sensitization in neuropathic 
conditions, and in the case of PC as well owing to their expression by keratinocytes.40,41 The events 
leading to peripheral sensitization often involve activation of pro-inflammatory substances and such 
were already introduced in association with PC pathology; keratinocytes from PC-affected skin might 
express higher levels of neurotrophic factors such as interleukin-18, that in turn can increase 
neuronal excitability.42,43 Peripheral sensitization can, in turn, lead to spontaneous and evoked pain 
as well as hypersensitivity to painful stimuli as reported by PC patients. 
It should be pointed out that the aforementioned positive and negative signs and symptoms are 
suggestive, but not pathognomonic for neuropathic pain. These signs and symptom fulfill two out of 
three levels of certainty in the diagnosis of neuropathic pain according to a recently revised grading 
system.22 The alterations in small unmyelinated nerve fibers in PC and the location of pain in the 
same regions seem to fulfill the possible neuropathic pain criteria. The presence of both negative 
and positive signs in the PC-affected regions (although the former to a lesser extent than the latter) 
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partly fulfill the next level of certainty- probable neuropathic pain. The level “probable” is suggested 
to be sufficient to initiate treatment according to neuropathic pain guidelines. The final level of 
certainty- definite neuropathic pain- requires that an objective diagnostic test confirming the 
lesion/disease of the somatosensory nervous system.22 While the sensory testing herein and skin 
biopsy analysis by Pan et al. may partly comply with such requirement a definite diagnosis is 
uncertain.  
Several limitations should be considered. First, the patients were not assessed at the time of PC 
diagnosis and therefore the results represent both primary and secondary consequences of any 
peripheral pathology that may have initiated the pain. Second, some features of the PC patients 
suggested that they may also experience chronic pain other than neuropathic. Third, the analgesic 
medications taken by about half of the patients may have affected the results although sensory 
testing of these patients were similar to those not taking such medications. In summary, the clinical 
examination and the sensory testing support the possibility that the chronic pain reported in the PC-
affected regions is- at least in part- of neuropathic origin. Medications aimed to reduce neuropathic 
pain may be useful for patients with PC. These may include, but not restricted to, tricyclic 
antidepressants, serotonin- noradrenaline reuptake inhibitors (SNRIs) and GABAergic agonists. 44 
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Figure legends 
Figure 1: Pathological sensations among the PC patients. Static allodynia, tingling and electric 
shock-like sensations were highly prevalent (95% confidence intervals of 42-67%, 39-68% and 32-
60%, respectively) whereas dynamic allodynia, paradoxical pain and hyperpathia were less frequent 
(95% confidence intervals of 11-44%, 5-37% and 2-32%, respectively). Bars denote percentages. 
 
Figure 2: Pain modulation among the PC patients. The magnitude of CPM (delta VAS) was 
significantly lower among patients with PC compared to healthy controls (**p<0.01). The magnitude 
of TSP (delta VAS) was similar across groups. Bars denote group mean ± SEM. 
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Table 1: Characteristics of the study groups and the chronic pain of PC patients 
 
 
 
 PC 
(n=62) 
Controls 
(n=45) 
P-value 
Age (mean±SD, years)  44.8 (16.4 P(  39.2 (15.5) 0.02 
Sex (males/females) 29/33 18/27 0.48 
Gene mutation (K6a/K16) 29/33 - - 
Duration of PC (mean±SD, years) 42.8 (17.8) - - 
Prevalence of chronic pain (yes, %) 53 (86%) - - 
Duration of chronic pain (mean±SD, years) 33.6 (22.3) - - 
Pain intensity by VAS (mean±SD, range 0-10) 5.7 (1.6) - - 
Pain intensity by MPQ (mean±SD) 22.3 (10.3) - - 
Pain during rest (yes, %)* 9 (17%) - - 
Pain during weight bearing (yes, %)* 50 (94.3) - - 
DN4 (mean±SD, range 0-10) 4.0 (2.6) - - 
PC= Pachyonychia Congenita, SD= standard deviation, VAS= visual analog scale, MPQ= McGill pain questionnaire, 
DN4= Douleur Neuropathique- 4 questionnaire, p-value: comparison between the groups (2-tailed). *Calculation out 
of out of the 53 patients with chronic pain. 
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Table 2: Average (±SD) of sensory and pain thresholds among the study groups  
 
 PC 
(n=62) 
Controls 
(n=45) 
P-value 
Upper limbs    
    Warm detection threshold (°C) 34.9 (0.9) 34.5 (1.1) <0.05 
    Cold detection threshold (°C) 29.9 (1.3) 30.7 (0.5) <0.001 
    Touch detection threshold (gf) 3.3 (0.5) 3.2 (0.6) 0.6 
    Heat-pain threshold (°C) 42.9 (3.2) 43.5 (3.0) 0.28 
Lower limb    
    Warm detection threshold (°C) 42.4 (4.5) 39.5 (3.3) <0.001 
    Cold detection threshold (°C) 25.8 (4.3) 29.2 (1.4) <0.0001 
    Touch detection threshold (gf) 3.6 (0.5) 3.4 (0.4) <0.05 
    Heat-pain threshold (°C) 47.4 (2.9) 46.5 (1.9) 0.11 
    Pressure-pain threshold (kPa)  195.3 (138)  429.6 (211) <0.0001 
PC= Pachyonychia Congenita, SD= standard deviation, p-value: comparison between the groups (2-tailed), 
kPa=kilopascal, gf=gram force 
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Table 3: Correlations coefficients within the PC group 
 
PC= Pachyonychia Congenita, DN4= Douleur Neuropathique-4, WDT=warm detection threshold, CDT=cold detection threshold, MDT=mechanical 
detection threshold, HPT=heat pain threshold, PPT=pressure pain threshold, CPM=conditioned pain modulation, TSP=temporal summation of pain. 
^p=0.055-0.065, *p<0.05, **p<0.01, ***p<0.0001 (2-tailed). In parentheses are 95% confidence intervals for significant, standardized coefficients. 
 
  Pain duration PC duration 
Pain 
intensity DN4 Age WDT CDT MDT HPT PPT 
PC 
duration 
.65
***
 
(0.39-0.81) 
         
Pain 
intensity 
-.44
**
 
(-0.61--0.27) 
-.03         
DN4 
-.1 .019 .08        
Age 
.65
***
 
(0.35-0.83) 
.98
*** 
(0.84-0.97) 
-.10 .03       
WDT 
.36
* 
(0.02-0.67) 
.22 -.07 .15 .22      
CDT 
-.49
**
 
(-0.68--0.13) 
.32^ .30^ -.00 -.18 -.55
*** 
(-0.69--0.29) 
    
MDT 
.07 .27 -.09 -.19 .17 .21 -.05    
HPT .06 .10 -.20 .28 -.00 
.65
*** 
(0.29-0.83) 
-.49
** 
-(0.92--0.13) 
.35   
PPT 
.34
*
 
(0.10-0.93) 
.21 -.33
^
 -.07 .25 -.04 -.12 -.17 .14  
CPM -0.1 -.03 .13 .00 .04 .05 .11 .04 -.25 
-0.31
*
 
(-0.40--0.1) 
TSP .204 -.01 -.01 -.07 -.05 -.09 -.04 
-.46
**
 
(-0.82--0.10) 
-.18 .04 
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Appendix 1: detailed study recruitment &v sample sizer calculations, inclusion criteria, 
sensory testing methods, statistical methods 
 
Recruitment and sample size: PC patients with mutations in KRT6A or KRT16 were 
recruited through the International Pachyonychia Congenita Research Registry (IPCRR). 
Healthy subjects were recruited among employees of the Tel-Aviv Medical Center as well as 
among members of the PC Project personnel. The sample size was calculated for specific 
power and α based on expected means and standard deviations (2-samples, 2-sided) 
separately for CPM and TSP and the larger sample size out of the two calculations was taken. 
The values were based on preliminary data and on our previous studies. For α=0.05 and 
statistical power of 80% the calculation yielded a sample size of 15 subjects and for α=0.01, 
19 subjects (effect size 0.79-0.87). Considering that the PC groups included people with two 
different mutations that required comparison, and considering that these tests were not 
previously done among patients with PC, the actual sample size was about two-fold that of 
the calculated one. 
Inclusion criteria for patients with PC were: 1) Age above 18 years, 2) Enrolled in the 
International Pachyonychia Congenita Research Registry (IPCRR) (WIRB 20040468), 3) 
Completion of genetic testing to confirm the diagnosis of PC [10], 4) Ability to understand 
and comply with the requirements of the investigators. Exclusion criteria for all subjects 
were: 1) Skin infections of the feet and forearms, 2) Diseases (other than PC for the patients) 
that may cause sensory abnormalities (e.g., diabetic peripheral neuropathy, 3) Pain 
complaints (other than those related to PC in the patients) that may confound the assessment 
(e.g., peripheral or central neuropathic pain conditions), 4) History of any unstable medical 
disease (e.g., cardiovascular or renal insufficiency), 5) History of significant psychiatric 
disease/disorder that could preclude reliable information as judged by the investigators. 
Methods for threshold measurements: Warm and cold detection thresholds were measured 
with the computerized thermal stimulator. Subjects received four successive stimuli of 
gradually increasing or decreasing temperatures, respectively, starting from a baseline 
temperature of 32°C (rate of 2°C/s), with an inter-stimulus-interval of 10 sec. The subjects 
were asked to press a switch when a thermal sensation (either warm or cold) was first 
perceived; thus, defining warm detection threshold and cold detection threshold and resetting 
the probe temperature to baseline values. Warm and cold thresholds were calculated as the 
average of four successive stimuli of each thermal sensation separately [12]. Mechanical 
detection threshold was measured with the Semmes-Weinstein monofilaments. The examiner 
applied the filaments in an increasing order, starting from the thinnest one. The subjects were 
asked to report when touch sensation was first perceived and at that point they were asked to 
localize the stimulus perceived. The threshold for touch was the calibrated force of the 
monofilament first perceived [13]. Heat-pain threshold was measured with the computerized 
thermal stimulator. Subjects received four successive stimuli of gradually increasing 
temperatures, starting from a baseline temperature of 32°C (rate of 2°C/s), with an inter-
stimulus-interval of 30 sec. The subjects were asked to press a switch when a pain sensation 
was first perceived; thus, defining the HPT and resetting the probe temperature to baseline 
values. HPT was the average reading of the four successive stimuli [12]. Pressure pain 
threshold (PPT) was measured with the pressure algometer using the modified method of 
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limits [14]. The tip of the pressure algometer probe was placed perpendicular over the skin. 
Gradual pressure was applied from a baseline intensity of 0 kPa at a rate of 30kpa/sec, with 
an inter-stimulus interval of 30 seconds. Subjects were instructed to press the switch when 
the first pain sensation was perceived, thus "freezing" the display with the corresponding 
pressure reading and recording it. PPT was the averaged reading of three successive stimuli 
of increasing pressure [14]. 
Methods for pain modulation measurement: For the CPM test, the TS was administered 
with the computerized thermal stimulator at an intensity equivalent to 2°C above the subject's 
individual HPT, for duration of 30 seconds, applied to the volar aspect of the forearm. The 
CS was immersing the contralateral hand in the cold water bath (10°C) for 40 seconds. First, 
the subjects gave pain ratings for the TS alone using the VAS, every 10 seconds. After 2 
minutes break, the contralateral hand was immersed in the water up to the wrist level, and 
after 10 seconds of hand immersion, the TS was applied a second time and VAS ratings were 
obtained. The magnitude of CPM was calculated by subtracting the average VAS rating of 
the TS in the presence of the CS from the average VAS rating of the TS alone [17]. 
Methods for evaluating pathological sensations: Static allodynia was examined by a single 
application of a monofilament no. 4.74 perpendicular on the skin and dynamic allodynia was 
tested by gently dragging the same monofilament along the subjects’ skin for 3 cm/1 sec. In 
both instances the subjects were asked to report the quality of sensation evoked by the 
stimulus [13]. Hyperpathia was tested in a sample of 30 PC patients with the thermal 
stimulator by gradually heating the skin from an adaptation temperature of 35
0
C at a rate of 
2/sec [13]. 
Questionnaires: The main component of the short form of the Mc'Gill pain questionnaire (SF-MPQ) 
consists of 15 descriptors divided into 11 sensory and 4 affective descriptors, which are rated on an 
intensity scale of 0 = none, 1 = mild, 2 = moderate or 3 = severe. Three pain scores are derived from 
the sum of the intensity rank values of the words chosen for sensory, affective and total descriptors. 
The SF-MPQ also includes the Present Pain Intensity (PPI) index of the standard MPQ and a visual 
analogue scale (VAS) [24]. The DN4 (Douleur Neuropathique-4) questionnaire includes a series of 
four questions consisting of both sensory descriptors and signs related to bedside sensory 
examination (total of 10 items). A score of 1 is given to each positive item and a score of 0 to each 
negative item. The total score is calculated as the sum of the 10 items and the cut-off value for the 
diagnosis of neuropathic pain is a total score of 4/10. 
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